Hovione has appointed Colin Minchom, formerly Patheon’s VP of Pharmaceutical Development Services for North America, as VP of its Particle Design Business Unit. Minchom has almost 30 years experience in drug development, especially in dosage forms and delivery, and is a member of the USP expert committee on small molecules. He is also chair of the planning committee for the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting.
“We are very pleased to welcome Dr. Minchom to Hovione,” commented Hovione CEO Guy Villax. “He is an excellent addition to our management team in an area of critical importance to our customers. Dr. Minchom is responsible for innovating Hovione’s Pharmaceutical Particle Design offerings to meet the development and commercial supply needs of the formulator with poorly bioavailable or otherwise challenging molecules.”
Minchom responded, “I look forward to building on what has been achieved by Hovione to date in its creation of solutions for customers needing Particle Design for improved bioavailability and also specialist delivery by non-oral routes.”
Read the Hovione press release.
